SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TokyoMex who wrote (2918)3/27/1998 10:22:00 PM
From: Charles J  Read Replies (1) of 34592
 
Secret Squirrel really nailed this one (SCLN).

Message 3535557

If your out their Lawrence keep us informed on Secrets Picks.

Did you notice the after hours release. SCLN keeps releasing better news between the continued lab success ZADAXIN is experiencing, its various applications and numerous country approvals. When they get their approval in Japan, they should do well.

For those of you not familiar with the company. Here is a quick summary.

SciClone currently markets ZADAXIN in three Asian countries -- the People's Republic of China, the Philippines and Singapore -- for the treatment of hepatitis B. In February 1998, ZADAXIN was approved in two Latin American countries -- Argentina and Peru -- as an influenza vaccine adjuvant and for treatment of hepatitis B, respectively. SciClone has 15 ZADAXIN NDAs pending in Asia, Latin America and the Middle East. SciClone's exclusive Japanese partner, Schering-Plough K.K.(SPKK), a subsidiary of Schering-Plough Corporation (NYSE: SGP - news), recently received government approval to commence a pivotal Phase 3 study of ZADAXIN as a monotherapy for hepatitis B.

biz.yahoo.com

Lawrence, hope you continue to share the wealth. Looking forward to the next one.

Still accumulating.

Thanks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News